Evaluation of the Effects of Losartan in Patients with Corona Virus Disease 2019

Abstract

Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Background: Several underlying diseases such as hypertension (HTN) are associated with increasing the risk of COVID-19 severity and are associated with a higher mortality rate. There are controversies regarding choice medication for the HTN control in patients with COVID-19. The aim of this study was comparing the effects of losartan and amlodipine in patients with primary HTN and COVID-19. Methods: In this randomized clinical trial study, patients with primary HTN and COVID-19 that admitted to the hospital were enrolled in the study. One group received losartan 25 mg twice daily and other group received amlodipine 5 mg per day for 2 weeks. Data were analyzed using IBM SPSS version 23. Results: 41 patients (22 male, 19 female) in losartan group and 39 patients (21 male, 18 female) in amlodipine group were recruited to the study. 22 patients in losartan group were male and 19 patients were female. Also, 21 patients in losartan group were male and 18 patients were female. The mean age of patients in losartan and amlodipine group was 67.3±14.8 and 60.1±17.3, respectively (P value: 0.068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = 0.994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = 0.241).